echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > How is the overall performance of the pharmaceutical sector in the near future? Obvious advantages of biopharmaceuticals

    How is the overall performance of the pharmaceutical sector in the near future? Obvious advantages of biopharmaceuticals

    • Last Update: 2019-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network pharmaceutical stock market] with the promotion of medical reform policies such as the expansion of volume procurement, the pharmaceutical segment has changed significantly It is understood that the three plates of medicine can be divided into Chinese patent medicine, chemical medicine and biological medicine So, so far, how about the overall performance of these three plates? According to the industry, among the three sectors, the growth rate of proprietary Chinese medicine is still at the bottom, while the biopharmaceutical sector has more advantages Growth rate of Chinese patent medicine is still at the bottom China's China one belt, one road development plan, the healthy China 2030 plan outline, the 13th Five-Year plan for the development of Chinese medicine, the white paper of Chinese medicine, and other important documents have been released in recent years, which can be seen in the support of the state's support for the Chinese medicine industry (2016-2030) Industry insiders predict that by 2020, China's large health industry of traditional Chinese medicine will exceed 3 trillion yuan, and the industry scale is expected to maintain 20% growth However, the performance of Chinese patent medicine plate is not satisfactory Data shows that Chinese patent medicine rose only 1.55% in the whole year Using non weighted statistics, Chinese patent medicine rose 8.46% According to the results of the first three quarters of this year's Chinese patent medicine industry, 44 out of 69 listed companies exceeded their expectations, accounting for 63.77% Another two listed companies lost money In addition, the whole sector has 27 stocks, net profit and negative growth, and 7 stocks of elite pharmaceutical, ST, and Long John pharmaceutical companies are cut off In this regard, the industry believes that from the perspective of stock price performance and business performance, Chinese patent medicine is the poor performance among the three major pharmaceutical sectors Biopharmaceutical sector has more advantages With the increasing support and encouragement of relevant policies and measures in the field of biopharmaceutical, the industry development is more standardized, and the market pattern changes, leading enterprises benefit from it Since 2019, many Biopharmaceutical Enterprises have achieved double growth of net profit and share price Biopharmaceuticals rose 43.57% in the whole year The biopharmaceutical sector rose 31.22% in non weighted terms Although inferior to chemical pharmaceutical, 10 shares of Changchun hi tech, Hualan biology, and kailaiying have reached a new record this year, which is the highest proportion among the three major pharmaceutical sectors Among them, Changchun Hi Tech rose 178.93% to close at 485.9 yuan this year According to the data, Changchun hi tech is mainly engaged in biomedicine and health industry, and mainly engaged in drug R & D, production and sales in the pharmaceutical field, covering a multi variety and multi product system from biopharmaceuticals, proprietary Chinese medicine to vaccine products In the first three quarters, the company achieved revenue of 5.444 billion yuan, a year-on-year increase of 31.5%; net profit attributable to the parent company was 1.241 billion yuan, a year-on-year increase of 47.93% The company expects production of varicella vaccine to meet sales in the second half of the year In addition, the company's nasal influenza vaccine has been reported for production and included in the priority approval The phase III clinical trial of herpes zoster vaccine is proceeding in an orderly manner, and the future market space is worth looking forward to Hualan biology achieved a net profit of 964 million yuan in the first three quarters, and its rapid growth in the third quarter was due to a larger volume of influenza vaccine than expected In addition, Hualan's rabies vaccine and tetanus vaccine have been put into production recently, and it is expected to bring new performance increment after coming into the market next year Kailaiying is engaged in the pharmaceutical industry In the first three quarters, the company achieved an operating revenue of 1.742 billion yuan, a year-on-year increase of 44.61%; the net profit attributable to shareholders of listed companies was 367 million yuan, a year-on-year increase of 40.48% In addition, all shares in biopharmaceutical sector have an average return on equity of 8.15% and an average gross margin of 64.92%, higher than that in chemical pharmaceutical sector.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.